Skip to main content

EUREKA grants awarded

Thirty-eight researchers were awarded with grants totaling $42.2 million dollars this week for their "linkurl:wild and crazy;https://www.the-scientist.com/blog/display/53456/ " ideas to change the way science is done. The EUREKA program (Exceptional, Unconventional Research Enabling Knowledge Acceleration), sought proposals from investigators that were linkurl:innovative,;https://www.the-scientist.com/article/display/54322/ but required little or no preliminary data. "There were so many good

Written byEdyta Zielinska
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Thirty-eight researchers were awarded with grants totaling $42.2 million dollars this week for their "linkurl:wild and crazy;https://www.the-scientist.com/blog/display/53456/ " ideas to change the way science is done. The EUREKA program (Exceptional, Unconventional Research Enabling Knowledge Acceleration), sought proposals from investigators that were linkurl:innovative,;https://www.the-scientist.com/article/display/54322/ but required little or no preliminary data. "There were so many good [projects]," said Jeremy Berg, director of the National Institute of General Medical Sciences (NIGMS), the largest funder of the four NIH institutes participating. "We ended up funding more than we thought." The institute had set aside $5 million, but awarded nearly $6 million in grants. A few of the winning projects: Beverly Davidson from University of Iowa will engineer RNA aptamers to act as specific drug delivery agents to carry chemical payloads into the brain, a notoriously difficult drug target. Akira Chiba, at the University of Miami, will investigate ways to stimulate neural regeneration by shaking things up, on the local level. Since researchers have seen mechanical force foster regeneration, Chiba's group propose using nanotechnology, bioengineering and genetics to restore neural connectivity in damaged areas of the brain via a mechanical instead of molecular approach. Alexander Varshavsky from the California Institute of Technology will investigate a novel way of globally targeting cancer, by engineering a molecule that looks for the gaps, or deletions, in the genome. Cancer therapies targeting specific genes often fail because of ongoing genetic mutation in the cancer cell; additionally, current therapies have severe side effects because they don't target cancer cells exclusively, but also attack biologically similar healthy cells. Varshavksy proposes using a hallmark of cancer cells -- deletion mutations -- to specifically target the cancer. Each project will receive up to $800,000 over four years. The program is already accepting applications for next year's round of awards; in 2009, nine of the 27 NIH institutes will participate, including NIGMS, rather than the four that participated this year.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • The Scientist Placeholder Image

    Edyta Zielinska was a senior editor at The Scientist from 2007 to 2013, where she worked closely with scientific illustrators to develop accompanying graphics to illuminate complex concepts. 

    View Full Profile
Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems
Optimizing NGS Library Preparation for Reliable Sequencing Data

Optimizing NGS Library Preparation for Reliable Sequencing Data

Covaris
Using TCR Repertoire Sequencing to Advance Immunology Research

Using TCR Repertoire Sequencing to Advance Immunology Research

Miltenyi

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo